GlassScriptPhysician profile
Prasad Pillai
NPI 1023174380
$8,140.56
in general payments reported to CMS, 2019-2025
62 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $593 · 2021: $496 · 2022: $1,127 · 2023: $973 · 2024: $1,417 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,717.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $842.73 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $697.66 | 2019-2025 | Opdivo |
| Pfizer INC. | $502.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $434.93 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $430.10 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $394.36 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Array Biopharma INC | $354.11 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Astellas Pharma US INC | $297.60 | 2019-2025 | Padcev, Xospata, Vyloy |
| Kite Pharma, INC. | $277.00 | 2020-2023 | |
| Glaxosmithkline, LLC. | $258.15 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Genzyme Corporation | $224.33 | 2020-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $216.15 | 2019-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $205.03 | 2019-2025 | Imfinzi, Enhertu |
| Genentech USA, INC. | $161.91 | 2019-2025 | Venclexta, Columvi, Polivy |
| Eisai INC. | $160.90 | 2019-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasad Pillai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.